We are live on ! Find out more
CLGN icon

CollPlant Biotechnologies
CLGN

2 hedge funds and large institutions have $21K invested in CollPlant Biotechnologies in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.13% more ownership

Funds ownership: 0.01% → 0.14% (+0.13%)

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

60% less capital invested

Capital invested by funds: $52K → $21K (-$31K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$14.2K
2
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$426

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$44K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$21K +$14.2K +3,521 +197%
Citadel Advisors
2
Citadel Advisors
Florida
– -$44K -11,119 Closed
HIIFS
3
Harel Insurance Investments & Financial Services
Israel
– +$426 +106 New

CLGN Hedge Fund Activity: Q3 2019 in Review

2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2019, worth a combined $21K — down 60% from $52K a quarter earlier.

Fund positioning in CLGN was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $14.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $44K sold.

  • 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $21K of CollPlant Biotechnologies stock for Q3 2019, down 60% quarter-over-quarter.
  • 1 fund opened new CollPlant Biotechnologies positions in Q3 2019 and 1 closed out, a net change of 0 holders.
  • The largest CollPlant Biotechnologies buyer in Q3 2019 was UBS Group, an estimated $14.2K added.
  • The largest CollPlant Biotechnologies seller in Q3 2019 was Citadel Advisors, an estimated $44K sold.

Based on aggregated 13F filings for Q3 2019.